2023 World Conference on Lung Cancer (Posters)-EP08.02. Real-World Disease-Free Survival (DFS) in Non-metastatic Non-small Cell Lung Cancer (NSCLC): A German I-O Optimise Analysis

EP08.02. Real-World Disease-Free Survival (DFS) in Non-metastatic Non-small Cell Lung Cancer (NSCLC): A German I-O Optimise Analysis - PDF(Abstract)

Back to course

Pdf Summary

This study analyzed the real-world disease-free survival (DFS) outcomes of patients with non-metastatic non-small cell lung cancer (NSCLC) who received adjuvant or neoadjuvant systemic anti-cancer therapy (SACT) in Germany. The study used data from four cancer registries in Germany and included patients diagnosed between January 2016 and December 2019, with follow-up until March 2022.<br /><br />A total of 2,660 patients were included in the study, with 19% receiving neoadjuvant SACT and 81% receiving adjuvant SACT. The patients were categorized based on their stage of NSCLC, with 6% having stage I, 33% having stage II, 41% having stage IIIA, 19% having stage IIIB, and 2% having stage IIIC.<br /><br />The study found that patients with stage I NSCLC who received adjuvant SACT had the longest median DFS, and it was not reached within the follow-up period. In stage IIIA patients receiving neoadjuvant SACT, those who received SACT alone had a longer median DFS compared to those who received SACT and radiotherapy. However, in stage IIIA patients receiving adjuvant SACT, the median DFS was similar between those who received SACT alone and those who received SACT and radiotherapy.<br /><br />These findings provide real-world evidence on DFS outcomes in patients with resectable non-metastatic NSCLC who underwent adjuvant or neoadjuvant SACT. The study highlights the importance of considering the stage of NSCLC and the type of SACT when determining the optimal treatment approach for these patients.<br /><br />Keywords: Disease-free survival, Adjuvant/neoadjuvant treatment, Real-world evidence.

Asset Subtitle

Melinda J Daumont

Meta Tag

Speaker Melinda J Daumont

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

Disease-free survival

Non-small cell lung cancer

NSCLC

Adjuvant treatment

Neoadjuvant treatment

Systemic anti-cancer therapy

SACT

Real-world evidence

Resectable NSCLC

Cancer registries